Categories: Volunteer Spotlight

Welcoming Dr. Aparna Parikh to our board of directors

Dr. Aparna Parikh, an assistant professor of medicine at Harvard University and medical-oncologist at Massachusetts General Hospital (MGH), is the newest member of the Binaytara Foundation board. Dr. Parikh has a longstanding interest in improving access to cancer care in low-to-middle-income countries (LMICs), and has spent time in several African countries, India and Haiti.  

Alongside caring for patients and pursuing translational research in GI oncology, she was named Director of the Mass General Cancer Center Global Cancer Program. In 2018, she co-founded an initiative called POETIC to bring trainees from Sub-Saharan Africa to MGH to help enhance their medical oncology training. She further supports oncologists from LMICs through American Society of Clinical Oncology’s IDEA (International Development and Education) program.

“I am thrilled to join the Board of a wonderful organization committed to advancing patient care in LMICs,” Dr. Parikh shares. “I hope over the career we will see a stark narrowing of the disparity gap for cancer patients and am excited to continue this work with Binaytara,” Dr. Parikh shares.”

BTF stands for the same virtues that Dr. Parikh and her work demonstrate–education, innovation, and advocacy.

“Dr. Parikh has a wealth of global oncology experience and is strongly committed to minimizing disparities in cancer care,” said Tara Shah, the executive director of the Binaytara Foundation. “I look forward to working alongside her and our other team members, supporters, and partners to improve access to evidence-based cancer care in resource-poor communities.” 

We are very excited about her taking a leadership role in the foundation and cannot wait to work with her on exciting projects that improve access to healthcare. Welcome, Dr. Parikh!

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

5 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

5 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

6 months ago